This finding also suggested that the FOXM1–TYMS axis might have a wider role in tumour progression, such as chemosensitivity, as TYMS is a cellular target of 5-FU, the first-line chemotherapeutic drug for CCA. Here, FOXM1 is linked to cholangiocarcinoma.